8-K: Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split to Regain Nasdaq Compliance

Pieris Pharmaceuticals has announced a 1-for-80 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Pieris Pharmaceuticals is implementing a 1-for-80 reverse stock split of its common stock.
• The reverse stock split is scheduled to be effective at 5:00 pm New York time on April 22, 2024.
• Trading on a split-adjusted basis will begin on April 23, 2024, under the existing ticker symbol PIRS.
• The primary reason for the reverse stock split is to increase the per share price above $1.00 to comply with Nasdaq listing rules.
• The company needs to maintain a share price above $1.00 for at least 10 consecutive trading days to regain full compliance.
• The reverse stock split will reduce the number of outstanding shares from 98,935,025 to approximately 1,236,688.
• The total authorized shares will be reduced from 300,000,000 to 3,750,000.
• Fractional shares resulting from the split will be rounded up to the nearest whole share.
• The CUSIP number for the common stock will change to 720795202.
• All outstanding options and warrants will be adjusted accordingly, with the number of shares reduced by a factor of 80 and the exercise price multiplied by 80.
• Preferred stock conversion prices will also be adjusted to maintain the same aggregate conversion price.

Sentiment

Score: 3

Explanation: The document indicates a negative situation requiring a reverse stock split to avoid delisting, which is generally not a positive sign for investors. While the company is taking steps to address the issue, the underlying problem of a low share price remains.

Positives

• The reverse stock split is a necessary step to regain compliance with Nasdaq listing rules, which could improve investor confidence.
• Rounding up fractional shares ensures that no shareholder loses out due to the split.
• The company is taking proactive steps to maintain its listing on the Nasdaq Capital Market.

Negatives

• The reverse stock split is a sign that the company's stock price has fallen below the minimum required by Nasdaq.
• The reduction in the number of outstanding shares could be perceived negatively by some investors.
• The need for a reverse stock split may indicate underlying financial challenges.

Risks

• There is no guarantee that the reverse stock split will successfully raise the stock price above $1.00 for the required 10 consecutive trading days.
• The company's ability to maintain its Nasdaq listing is still uncertain.
• The company's updated corporate strategy, announced in March 2024, may present additional risks.
• The company is seeking potential acquirers for its remaining preclinical and clinical assets, which may not be successful.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement and is seeking potential acquirers for its remaining assets. The company's future success depends on maintaining its listing and the outcome of its strategic review.

Management Comments

• The Board of Directors approved the 1-for-80 reverse stock split.
• The company is effectuating the reverse stock split to raise the per share bid price of the company's common stock above $1.00 per share.
• The company will have regained compliance once the company's common stock trades at or above $1.00 for a minimum of 10 consecutive trading days.

Industry Context

Reverse stock splits are often used by companies facing delisting from major exchanges due to low share prices. This action is not uncommon in the biotechnology sector, where companies can experience significant volatility and may need to take steps to maintain their listing status.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies to regain compliance with exchange listing requirements, particularly when facing delisting due to low share prices.
• Other biotech companies facing similar challenges have also implemented reverse stock splits, such as Cassava Sciences (SAVA) which had a 1-for-5 reverse split in 2019 and Ocugen (OCGN) which had a 1-for-10 reverse split in 2023.
• The 1-for-80 ratio is relatively high, indicating a significant drop in the company's share price and a more urgent need to regain compliance compared to companies with lower reverse split ratios.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their proportional ownership will remain virtually unchanged.
• The reverse stock split is intended to benefit shareholders by maintaining the company's listing on Nasdaq.
• Employees may be affected by the company's overall financial situation and strategic review.
• Customers and suppliers may be indirectly affected by the company's financial health and strategic direction.

Next Steps

• The reverse stock split will be effective on April 22, 2024.
• The company's stock will begin trading on a split-adjusted basis on April 23, 2024.
• The company needs to maintain a share price above $1.00 for 10 consecutive trading days to regain full compliance with Nasdaq listing rules.
• Stockholders holding physical certificates need to send them to Computershare to receive new shares in book-entry form.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, minimum bid price, stock listing, share price, PIRS, common stock, stock options, warrants, preferred stock